Jiangsu Alphamab Biopharmaceuticals Co., Ltd
43
8
10
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
23.3%
10 terminated/withdrawn out of 43 trials
47.4%
-39.2% vs industry average
14%
6 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (43)
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
Role: lead
A Phase I Study of JSKN021 in Advanced Solid Tumors
Role: lead
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Role: lead
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
Role: collaborator
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Role: lead
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Role: lead
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Role: lead
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
Role: lead
A Study of JSKN027 in Patients With Advanced Solid Tumors
Role: lead
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Role: lead
JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
Role: lead
JSKN022 in Subjects With Advanced Malignant Solid Tumors
Role: lead
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Role: lead
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Role: lead
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Role: lead
TATE and KN046 in MCRC
Role: collaborator
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Role: lead
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Role: lead
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Role: lead